Halting Cancer by Halting DNA Repair

September 25, 2020 11:00 am

By Liam Drew

PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more

Immunotherapy Falls Short Again in Ovarian Cancer

September 23, 2020 6:00 pm

No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.

By Charles Bankhead

An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more

Why Some Cancers May Respond Poorly to Key Drugs Discovered

September 22, 2020 4:00 pm

Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of Texas at Austin and Ajou University … Read more

Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer

September 18, 2020 3:00 pm

Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more

Phase I Data of XMT-1536 Supports Continued Development in Ovarian Cancer

September 17, 2020 1:00 pm

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536 show a 34% objective response rate (ORR) and 79% disease control rate, including two complete responses. … Read more

The Clearity Foundation Teams Up With Select Justice To Help Families Impacted By Ovarian Cancer

September 13, 2020 9:00 am

When a loved one is diagnosed with ovarian cancer, it has a profound effect on their lives and their families’ lives. As quickly as the patient receives her diagnosis, her family members immediately slip into caregivers’ roles, often without warning Read more

PARP Inhibitors Deemed Too Costly For Across-the-Board Frontline Maintenance in Ovarian Cancer

September 11, 2020 8:00 pm

By Leah Lawrence

A new study estimated that a PARP inhibitor-for-all approach to treating advanced-stage ovarian cancer would be associated with high costs compared with biomarker-directed use of PARP inhibitors.1 Study researchers recommended that maintenance treatment with PARP inhibitors … Read more

Patient-Reported Outcomes for Rucaparib as a Maintenance Therapy in Recurrent Ovarian Cancer

September 3, 2020 5:00 pm

By Susan Moench, PhD, PA-C

Results of an exploratory analysis showed longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in women with recurrent ovarian cancer treated with maintenance use of the poly(ADP-ribose) polymerase (PARP) inhibitor, … Read more

ASCO Releases New Guidelines on PARP Inhibitor Use for Management of Ovarian Cancer

September 1, 2020 2:00 pm

By Hannah Slater

The recommendations were based on a review of 17 clinical trials, FDA approvals, and consensus where evidence was lacking.

The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the … Read more

San Diego County Administration Building Turns Teal on Sept. 1

September 1, 2020 7:00 am

San Diego’s Teal Women Honored in Historic Gesture in Support of Ovarian Cancer Survivors

September is National Ovarian Cancer Awareness Month and, in recognition, the County of San Diego Administration Center building will be turning its lights the color teal.

Read more

Research Discovery May Offer New Treatment Options for People Diagnosed With Rare Form of Ovarian Cancer

August 26, 2020 8:00 am

A recent finding by researchers at UBC’s faculty of medicine and the BC Cancer Research Institute (BCCRI) may offer a new treatment possibility for people diagnosed with a rare and aggressive form of ovarian cancer.

Small cell carcinoma of the … Read more

HIPEC With Cytoreductive Surgery Effective in Ovarian Cancer

August 25, 2020 5:00 pm

By Sarah Williams

For patients with stage III epithelial ovarian cancer, adding hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) increases survival compared with PCS alone, according to results of a retrospective study now published in JAMA Network OpenRead more

STING Activation Touted as Potential Immunotherapy for Cancer

August 25, 2020 9:00 am

A Scripps Research team reports the discovery of a molecule that can activate a natural immune-boosting protein called STING. The findings mark a key advance in the field of oncology, as the STING protein is known for its strong antitumor … Read more

Tumor Gene Test Could Help to Predict Ovarian Cancer Prognosis

August 17, 2020 6:00 pm

A global team of medical researchers led by UNSW have developed a test that could help to predict survival for women diagnosed with ovarian cancer, and pave the way towards personalised treatment.

A tumour test could help to identify ovarian … Read more

Local Resident Oversees Potential COVID-19 Pneumonia Treatment

August 10, 2020 1:00 pm

By Luke Harold

As chairman and CEO of CalciMedica, Rachel Leheny is overseeing the development of a potential treatment for organ damage caused by COVID-19 pneumonia.

“Our lead compound Auxora is in clinical development in COVID-19 pneumonia,” said Leheny, who … Read more

Study Finds Patients With Rare Ovarian Cancer Develop Chemoresistance

August 7, 2020 5:00 pm

By Christina Bennett, MS

Patients with LGSC also had a significantly lower partial response rate with neoadjuvant therapy compared with patients with HGSC.

Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy,

Read more

Be The Difference Foundation Announces Collaboration With Mary Crowley Cancer Research and The Clearity Foundation to Increase Support For Clinical Trial Participants

July 31, 2020 11:00 am

New “Caring For Her” program facilitates access to clinical trials and psychosocial support services for women with ovarian cancer.

Be The Difference Foundation today announced the launch of its “Caring For Her” program in partnership with Mary Crowley Cancer Research

Read more

How Does Ovarian Cancer Form? A New Study Points to MicroRNA

July 30, 2020 4:00 pm

Although ovarian cancer is the fifth-leading cause of death from cancer in women, scientists don’t have a good handle on how it forms. Now a new study suggests that a microRNA—a molecule made by cells to turn genes on … Read more

Chemotherapy, Surgery for Gynecologic Cancer Not Linked to Higher COVID-19 Mortality Risk

July 30, 2020 3:00 pm

Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.

However, recent immunotherapy use … Read more

If You Feel Something, Say Something

July 28, 2020 5:00 pm

Have you ever had a doctor roll his or her eyes or give you the brushoff after mentioning a health concern? If you’re like many women, it may not have been your imagination. As more and more research comes out … Read more